Bellicum prices $60M follow-on

Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) raised $60 million through the sale of 8 million shares at $7.50 in a follow-on underwritten by Citigroup, Jefferies, Guggenheim, Ladenburg Thalmann and Raymond James. The price is a 16% discount to Bellicum's closing price of $8.97 on Monday, when it proposed the offering after market hours.

Bellicum gained 20% to $8.24 on April 12 after FDA lifted a clinical hold on lead candidate BPX-501, an adjunct T cell therapy consisting of genetically modified donor T cells. The therapy is in Phase I and Phase I/II trials to prevent graft-versus-host disease (GvHD) in patients with hematological malignancies undergoing partial match hematopoietic stem cell transplants (HSCTs) (see BioCentury Extra, April 11)...